Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA.

Mol Cancer Res. 2019 Nov;17(11):2154-2168. doi: 10.1158/1541-7786.MCR-18-0605. Epub 2019 Aug 8.

PMID:
31395667
2.

Using online game-based platforms to improve student performance and engagement in histology teaching.

Felszeghy S, Pasonen-Seppänen S, Koskela A, Nieminen P, Härkönen K, Paldanius KMA, Gabbouj S, Ketola K, Hiltunen M, Lundin M, Haapaniemi T, Sointu E, Bauman EB, Gilbert GE, Morton D, Mahonen A.

BMC Med Educ. 2019 Jul 22;19(1):273. doi: 10.1186/s12909-019-1701-0.

3.

Axon Guidance-Related Factor FLRT3 Regulates VEGF-Signaling and Endothelial Cell Function.

Jauhiainen S, Laakkonen JP, Ketola K, Toivanen PI, Nieminen T, Ninchoji T, Levonen AL, Kaikkonen MU, Ylä-Herttuala S.

Front Physiol. 2019 Mar 12;10:224. doi: 10.3389/fphys.2019.00224. eCollection 2019.

4.

CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells.

Härkönen K, Oikari S, Kyykallio H, Capra J, Hakkola S, Ketola K, Thanigai Arasu U, Daaboul G, Malloy A, Oliveira C, Jokelainen O, Sironen R, Hartikainen JM, Rilla K.

Cells. 2019 Mar 22;8(3). pii: E276. doi: 10.3390/cells8030276.

5.

Recurrent On-Duty Sleepiness and Alertness Management Strategies in Long-Haul Airline Pilots.

Sallinen M, Åkerstedt T, Härmä M, Henelius A, Ketola K, Leinikka M, Kecklund G, Sihvola M, Tuori A, Virkkala J, Puttonen S.

Aerosp Med Hum Perform. 2018 Jul 1;89(7):601-608. doi: 10.3357/AMHP.5092.2018.

PMID:
29921351
6.

Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.

Ketola K, Munuganti RSN, Davies A, Nip KM, Bishop JL, Zoubeidi A.

Clin Cancer Res. 2017 Nov 15;23(22):6923-6933. doi: 10.1158/1078-0432.CCR-17-0901. Epub 2017 Sep 12.

7.

Targeting Lyn regulates Snail family shuttling and inhibits metastasis.

Thaper D, Vahid S, Nip KM, Moskalev I, Shan X, Frees S, Roberts ME, Ketola K, Harder KW, Gregory-Evans C, Bishop JL, Zoubeidi A.

Oncogene. 2017 Jul 13;36(28):3964-3975. doi: 10.1038/onc.2017.5. Epub 2017 Mar 13.

PMID:
28288135
8.

High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

Ketola K, Viitala M, Kohonen P, Fey V, Culig Z, Kallioniemi O, Iljin K.

J Mol Biochem. 2016 Mar 30;5(1):12-22.

9.

Sleep, alertness and alertness management among commercial airline pilots on short-haul and long-haul flights.

Sallinen M, Sihvola M, Puttonen S, Ketola K, Tuori A, Härmä M, Kecklund G, Åkerstedt T.

Accid Anal Prev. 2017 Jan;98:320-329. doi: 10.1016/j.aap.2016.10.029. Epub 2016 Nov 2.

PMID:
27816011
10.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

11.

Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.

Bishop JL, Davies A, Ketola K, Zoubeidi A.

Endocr Relat Cancer. 2015 Jun;22(3):R165-82. doi: 10.1530/ERC-15-0137. Epub 2015 May 1. Review.

PMID:
25934687
12.

A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME.

Oncotarget. 2013 Apr;4(4):502-30. Review.

13.

High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.

Lehtinen L, Ketola K, Mäkelä R, Mpindi JP, Viitala M, Kallioniemi O, Iljin K.

Oncotarget. 2013 Jan;4(1):48-63.

14.

Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.

Ketola K, Kallioniemi O, Iljin K.

PLoS One. 2012;7(12):e51470. doi: 10.1371/journal.pone.0051470. Epub 2012 Dec 12.

15.

Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress.

Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, Kallioniemi O, Iljin K.

Br J Cancer. 2012 Jan 3;106(1):99-106. doi: 10.1038/bjc.2011.530.

16.

Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, Fey V, Perälä M, Smit F, Verhaegh G, Schalken J, Alanen KA, Kallioniemi O, Iljin K.

Am J Pathol. 2011 Feb;178(2):525-36. doi: 10.1016/j.ajpath.2010.10.002.

17.

Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells.

Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K.

Mol Cancer Ther. 2010 Dec;9(12):3175-85. doi: 10.1158/1535-7163.MCT-10-0368.

18.

High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O.

Clin Cancer Res. 2009 Oct 1;15(19):6070-8. doi: 10.1158/1078-0432.CCR-09-1035. Epub 2009 Sep 29.

19.

PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.

Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, Raheem O, Ketola K, Lin S, Kast J, Haapasalo H, Hahn WC, Westermarck J.

Cancer Res. 2009 Apr 1;69(7):2870-7. doi: 10.1158/0008-5472.CAN-08-2760. Epub 2009 Mar 17.

20.

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.

Luomanmäki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sörskog L, Vilkko P.

J Intern Med. 1996 Aug;240(2):85-92.

PMID:
8810934
21.

Effect of 3He on the wetting of 4He to a cesium-coated substrate.

Ketola KS, Hallock RB.

Phys Rev Lett. 1993 Nov 15;71(20):3295-3298. No abstract available.

PMID:
10054937
22.

Anomalous wetting of helium on cesium.

Ketola KS, Wang S, Hallock RB.

Phys Rev Lett. 1992 Jan 13;68(2):201-204. No abstract available.

PMID:
10045561
23.

Machiavellianism and evaluation of cognitively balanced/unbalanced situations.

Sorem AM, Ketola K.

Psychol Rep. 1977 Apr;40(2):663-5. No abstract available.

PMID:
859986

Supplemental Content

Loading ...
Support Center